Top Markets
Coin of the day
Zhejiang Taimei Medical Technology Co., Ltd. Zhejiang Taimei Medical Technology Co., Ltd.

Zhejiang Taimei Medical Technology Co., Ltd.

2576
Clasificación en acciones #15029
Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in... Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.
Precio por acción
$0.67033345
Capitalización bursátil
$377.97M
Cambio (1 día)
-3.68%
Cambio (1 año)
5.38%
País
CN
Comercio Zhejiang Taimei Medical Technology Co., Ltd. (2576)

Categoría

Ratio P/E de Zhejiang Taimei Medical Technology Co., Ltd. (2576)
Ratio P/E al 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Zhejiang Taimei Medical Technology Co., Ltd., el P/E actual (TTM) de la empresa es 0. Al final de 2026, la empresa tenía un P/E de 0.
Historial del ratio P/E de Zhejiang Taimei Medical Technology Co., Ltd. desde 2026 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
Not enough data for the provided dates.
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
27.13 -
DE
23.41 -
US
- -
CA
16.34 -
US
91.92 -
US
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.